The Medicines Company Announces HORIZONS-AMI 1-Year Data To Be Presented at 2008 TCT Meeting

WASHINGTON--(BUSINESS WIRE)-- The Medicines Company (NASDAQ:MDCO) -- today announced that 1-year clinical data from the HORIZONS-AMI trial, comparing Angiomax® (bivalirudin) vs. unfractionated heparin (UFH) plus glycoprotein IIb/IIIa Inhibitors (GPI), will be presented in a late-breaker presentation on October 15, 2008 in a session that begins at 11 am at the 2008 Transcatheter Cardiovascular Therapeutics (TCT) Conference, which is being held from Oct. 12 – Oct. 17, 2008, in Washington D.C. This marks another significant milestone in the release of new clinical data around the treatment of heart attacks.